The Effect of Long-Term Sodium-Glucose Cotransporter 2 Inhibitor Treatment on Renal Function in Patients with Type 2 Diabetes
10.4093/jkd.2020.21.3.105
- Author:
Jong Ha BAEK
1
;
Tae Jung OH
;
Ju-Young MOON
;
Taehee KIM
;
Seung Hyun KO
;
Min Kyong MOON
;
Hyun Jung KIM
;
Dong Won LEE
;
Kyu Yeon HUR
;
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea
- Publication Type:Guideline
- From:Journal of Korean Diabetes
2020;21(3):105-115
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Chronic kidney disease commonly develops in patients with type 2 diabetes mellitus (T2DM) and is the most common cause of end-stage renal disease and related cardiovascular complications. Meanwhile, despite the current standard of care that includes optimized glucose control and the use of single-agent blockade of the renin-angiotensin-aldosterone system (RAAS), patients with T2DM remain at increased risk for premature death and complications due to cardiorenal causes. Recent studies using sodiumglucose cotransporter 2 (SGLT2) inhibitors have shown not only glucose lowering effects, but also a reduction in blood pressure, weight loss, and lower cardiovascular risk. Regarding renal outcomes, the use of SGLT2 inhibitors slows the progression of kidney disease compared to placebo when added to standard care. However, concern has been raised that currently available SGLT2 inhibitors in Korea may also be associated with improved renal outcomes during long-term treatment. As a result, we aimed to evaluate the effect of long-term SGLT2 inhibitor treatment on renal function in patients with T2DM using meta-analysis.
